Cargando…
Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice
Bendamustine has demonstrated clinical activity and a favorable safety profile as monotherapy or in combination with rituximab in lymphoid malignancies. As interventional trials do not always reflect clinical reality, we were interested in the treatment modalities and the outcome of bendamustine-bas...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525187/ https://www.ncbi.nlm.nih.gov/pubmed/26122866 http://dx.doi.org/10.1007/s00277-015-2404-1 |
_version_ | 1782384287305170944 |
---|---|
author | Becker, M. Tschechne, B. Reeb, M. Schwinger, U. Bruch, H.-R. Frank, M. Straßl, L. |
author_facet | Becker, M. Tschechne, B. Reeb, M. Schwinger, U. Bruch, H.-R. Frank, M. Straßl, L. |
author_sort | Becker, M. |
collection | PubMed |
description | Bendamustine has demonstrated clinical activity and a favorable safety profile as monotherapy or in combination with rituximab in lymphoid malignancies. As interventional trials do not always reflect clinical reality, we were interested in the treatment modalities and the outcome of bendamustine-based first-line therapy in patients with advanced indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL) in routine practice. Between April 2010 and October 2011, 324 patients were enrolled in a prospective non-interventional multicenter study. Choice of the bendamustine regimen was at the treating physician’s discretion. Effectiveness was assessed by best response. Mean age at onset of therapy was 69 years. The majority (94 %) of the patients was treated with bendamustine in combination with rituximab at a median bendamustine dose of 177 mg/m(2) per cycle. Most often, bendamustine was administered on days 1 and 2 (87 %) at 4-week intervals over a median of 6 cycles. Two hundred eighty-one patients qualified for evaluation of response. The overall response rate was 86 % (complete response 43 %, partial response 43 %, stable disease 10 %, progressive disease 4 %). Side effects of all grades were documented for 161 of the 323 patients (50 %), most frequently affecting blood/bone marrow (35 %). Fifty-four (17 %) patients experienced side effects of grade 3 (15 %) or grade 4 (2 %), and two patients grade 5 toxicities. Bendamustine-based first-line treatment of patients with advanced indolent NHL and MCL in clinical routine practice was assessed as effective and well tolerated in our study. Response was comparable to results from interventional clinical trials. |
format | Online Article Text |
id | pubmed-4525187 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-45251872015-08-06 Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice Becker, M. Tschechne, B. Reeb, M. Schwinger, U. Bruch, H.-R. Frank, M. Straßl, L. Ann Hematol Original Article Bendamustine has demonstrated clinical activity and a favorable safety profile as monotherapy or in combination with rituximab in lymphoid malignancies. As interventional trials do not always reflect clinical reality, we were interested in the treatment modalities and the outcome of bendamustine-based first-line therapy in patients with advanced indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL) in routine practice. Between April 2010 and October 2011, 324 patients were enrolled in a prospective non-interventional multicenter study. Choice of the bendamustine regimen was at the treating physician’s discretion. Effectiveness was assessed by best response. Mean age at onset of therapy was 69 years. The majority (94 %) of the patients was treated with bendamustine in combination with rituximab at a median bendamustine dose of 177 mg/m(2) per cycle. Most often, bendamustine was administered on days 1 and 2 (87 %) at 4-week intervals over a median of 6 cycles. Two hundred eighty-one patients qualified for evaluation of response. The overall response rate was 86 % (complete response 43 %, partial response 43 %, stable disease 10 %, progressive disease 4 %). Side effects of all grades were documented for 161 of the 323 patients (50 %), most frequently affecting blood/bone marrow (35 %). Fifty-four (17 %) patients experienced side effects of grade 3 (15 %) or grade 4 (2 %), and two patients grade 5 toxicities. Bendamustine-based first-line treatment of patients with advanced indolent NHL and MCL in clinical routine practice was assessed as effective and well tolerated in our study. Response was comparable to results from interventional clinical trials. Springer Berlin Heidelberg 2015-06-28 2015 /pmc/articles/PMC4525187/ /pubmed/26122866 http://dx.doi.org/10.1007/s00277-015-2404-1 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Becker, M. Tschechne, B. Reeb, M. Schwinger, U. Bruch, H.-R. Frank, M. Straßl, L. Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice |
title | Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice |
title_full | Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice |
title_fullStr | Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice |
title_full_unstemmed | Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice |
title_short | Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice |
title_sort | bendamustine as first-line treatment in patients with advanced indolent non-hodgkin lymphoma and mantle cell lymphoma in german routine clinical practice |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525187/ https://www.ncbi.nlm.nih.gov/pubmed/26122866 http://dx.doi.org/10.1007/s00277-015-2404-1 |
work_keys_str_mv | AT beckerm bendamustineasfirstlinetreatmentinpatientswithadvancedindolentnonhodgkinlymphomaandmantlecelllymphomaingermanroutineclinicalpractice AT tschechneb bendamustineasfirstlinetreatmentinpatientswithadvancedindolentnonhodgkinlymphomaandmantlecelllymphomaingermanroutineclinicalpractice AT reebm bendamustineasfirstlinetreatmentinpatientswithadvancedindolentnonhodgkinlymphomaandmantlecelllymphomaingermanroutineclinicalpractice AT schwingeru bendamustineasfirstlinetreatmentinpatientswithadvancedindolentnonhodgkinlymphomaandmantlecelllymphomaingermanroutineclinicalpractice AT bruchhr bendamustineasfirstlinetreatmentinpatientswithadvancedindolentnonhodgkinlymphomaandmantlecelllymphomaingermanroutineclinicalpractice AT frankm bendamustineasfirstlinetreatmentinpatientswithadvancedindolentnonhodgkinlymphomaandmantlecelllymphomaingermanroutineclinicalpractice AT straßll bendamustineasfirstlinetreatmentinpatientswithadvancedindolentnonhodgkinlymphomaandmantlecelllymphomaingermanroutineclinicalpractice |